{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:24:24Z","timestamp":1747196664875,"version":"3.40.5"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Sodium-glucose co-transporter-2 (SGLT2) inhibitors such as Empagliflozin, are increasingly recommended as part of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) in many developed nations. This recommendation is based on robust clinical evidence showing that adding Empagliflozin to GDMT improves heart failure symptoms, clinical outcomes, functional status, and overall quality of life. In Malaysia, where healthcare is predominantly public and heavily subsidized, the introduction of new treatments can significantly impact costs, requiring detailed economic assessments. This study evaluates the budget impact of incorporating Empagliflozin into GDMT for HFrEF from the perspective of the public healthcare system. A five-year budget impact model was developed, integrating local data such as population, drug use, costs, clinical outcomes, and healthcare expenses. In the current scenario (GDMT alone), the projected five-year expenditure is MYR 6.12 billion (USD 3.92 billion). With Empagliflozin, the total cost rises by 0.71% to MYR 6.16 billion (USD 3.95 billion), driven by drug acquisition costs of MYR 160.12 million (USD 102.64 million) and adverse event costs of MYR 211,543 (USD 135,604). However, these costs are offset by savings from reduced HF hospitalizations, fewer cardiovascular deaths, and improved renal outcomes. Sensitivity analysis identified hospitalization costs, the price of Empagliflozin, and cardiovascular deaths in diabetic patients as key factors influencing the budget impact. Policymakers can improve the affordability of Empagliflozin through strategies like price negotiations, cost-sharing, and focusing on high-risk groups to optimize healthcare expenditure while ensuring effective treatment access.<\/jats:p>","DOI":"10.1371\/journal.pone.0313131","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:36:59Z","timestamp":1730396219000},"page":"e0313131","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the budget impact of Empagliflozin in managing heart failure with reduced ejection fraction: Proposing strategic policies for Malaysian public healthcare"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3877-5743","authenticated-orcid":true,"given":"Vee Sim","family":"Yong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2010-5593","authenticated-orcid":true,"given":"Sivaraj","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia How","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6530-8677","authenticated-orcid":true,"given":"Mohd Shahri","family":"Bahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-8235","authenticated-orcid":true,"given":"Nur Amalina","family":"Zaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houng Bang","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"pone.0313131.ref001","doi-asserted-by":"crossref","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"G. Lippi","year":"2020","journal-title":"AME Med J"},{"key":"pone.0313131.ref002","first-page":"2020","article-title":"Heart Failure with Reduced Ejection Fraction: A Review","volume":"04","author":"S. P. Murphy","journal-title":"American Medical Association"},{"key":"pone.0313131.ref003","article-title":"Clinical Practice Guidelines: Management of Heart Failure (4th Edition 2019)","author":"National Heart Association Malaysia","year":"2019","journal-title":"National Heart Association of Malaysia"},{"author":"H. Zainal Abidin","key":"pone.0313131.ref004","article-title":"Demographic characteristics differences across EF subgroups in the Malaysian heart failure (MyHF) registry"},{"issue":"4","key":"pone.0313131.ref005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.hfc.2015.07.006","article-title":"Prognostic Factors in Hospitalization for Heart Failure in Asia","volume":"11","author":"S.-M. Kang","year":"2015","journal-title":"Heart Fail Clin"},{"key":"pone.0313131.ref006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2016.07.256","article-title":"Heart failure across Asia: same healthcare burden but differences in organization of care","volume":"223","author":"E. B. Reyes","year":"2016","journal-title":"Int J Cardiol"},{"issue":"7","key":"pone.0313131.ref007","article-title":"Financial burden of heart failure in Malaysia: A perspective from the public healthcare system","volume":"18","author":"S. C. Ong","year":"2023","journal-title":"PLoS One"},{"key":"pone.0313131.ref008","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"T. A. McDonagh","year":"2021","journal-title":"Oxford University Press"},{"key":"pone.0313131.ref009","first-page":"2022","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"01","author":"D. Tomasoni","journal-title":"John Wiley and Sons Ltd"},{"issue":"15","key":"pone.0313131.ref010","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"M. Packer","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0313131.ref011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"P. A. Heidenreich","year":"2022","journal-title":"Lippincott Williams and Wilkins"},{"issue":"4","key":"pone.0313131.ref012","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results from the EMPEROR-Reduced Trial","volume":"143","author":"S. D. Anker","year":"2021","journal-title":"Circulation"},{"article-title":"MANAGEMENT OF HEART FAILURE 2023 5th Edition CLINICAL PRACTICE GUIDELINES","year":"2023","author":"National Heart Association of Malaysia","key":"pone.0313131.ref013"},{"key":"pone.0313131.ref014","article-title":"Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System","author":"Y. J. Tan","year":"2024","journal-title":"Clin Ther"},{"issue":"1","key":"pone.0313131.ref015","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.jval.2021.11.530","article-title":"POSC126 Budget Impact Analysis of Adopting Sodium-Glucose Cotransporter-2 Inhibitor for Treatment of Type 2 Diabetes Mellitus in Ministry of Health Malaysia","volume":"25","author":"N. Idrus","year":"2022","journal-title":"Value in Health"},{"author":"International Trade Administration","key":"pone.0313131.ref016","article-title":"Healthcare Resource Guide Malaysia"},{"issue":"1","key":"pone.0313131.ref017","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis\u2014Principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"S. D. Sullivan","year":"2014","journal-title":"Value in Health"},{"issue":"5","key":"pone.0313131.ref018","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s12325-021-01681-2","article-title":"Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event","volume":"38","author":"A. Alsumali","year":"2021","journal-title":"Adv Ther"},{"key":"pone.0313131.ref019","unstructured":"PHARMACOECONOMIC GUIDELINES FOR MALAYSIA 2019 Second Edition MINISTRY OF HEALTH MALAYSIA. [Online]. Available: http:\/\/www.pharmacy.gov.my\/v2\/ms"},{"key":"pone.0313131.ref020","unstructured":"Department of Statistics Malaysia (DOSM), \u201cVital Statistics Malaysia 2023.\u201d [Online]. Available: https:\/\/open.dosm.gov.my."},{"issue":"15","key":"pone.0313131.ref021","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"N. L. Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"pone.0313131.ref022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2021.10.055","article-title":"Malaysian Heart Failure (MYHF) Registry substantiates high burden of comorbidities across the continuum of ejection fraction in Malaysian HF patients","volume":"345","author":"A. Henry","year":"2021","journal-title":"Int J Cardiol"},{"key":"pone.0313131.ref023","unstructured":"\u201cJARDIANCE (Empagliflozin), Boehringher Ingelheim International GmBH;9\/2023.\u201d [Online]. Available: www.fda.gov\/medwatch."},{"issue":"11","key":"pone.0313131.ref024","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial","volume":"77","author":"M. Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"pone.0313131.ref025","article-title":"Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study","volume":"9","author":"S. C. Ong","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"pone.0313131.ref026","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12325-016-0454-y","article-title":"Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts","volume":"34","author":"E. N. Obi","year":"2017","journal-title":"Adv Ther"},{"issue":"1","key":"pone.0313131.ref027","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-020-01966-8","article-title":"Prevalence of chronic kidney disease and its associated factors in Malaysia; Findings from a nationwide population-based cross-sectional study","volume":"21","author":"T. A. Saminathan","year":"2020","journal-title":"BMC Nephrol"},{"key":"pone.0313131.ref028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.vhri.2017.06.002","article-title":"The Cost and Quality of Life of Malaysian Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease and Anemia","volume":"15","author":"S. Azmi","year":"2018","journal-title":"Value Health Reg Issues"},{"issue":"7","key":"pone.0313131.ref029","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1016\/j.jval.2022.04.746","article-title":"EE499 Budget Impact Analysis of Empagliflozin in Patients with Heart Failure in Sweden","volume":"25","author":"V. Kontogiannis","year":"2022","journal-title":"Value in Health"},{"key":"pone.0313131.ref030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vhri.2022.08.012","article-title":"Economic Evaluation Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa","volume":"33","author":"J. Catharina De Beer","year":"2023","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"pone.0313131.ref031","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: A systematic review 2004\u20132016","volume":"18","author":"W. Lesyuk","journal-title":"BMC Cardiovasc Disord"},{"author":"K. K. Malaysia","key":"pone.0313131.ref032","article-title":"PROGRAM PERKHIDMATAN FARMASI PHARMACEUTICAL SERVICES PROGRAMME"},{"issue":"1","key":"pone.0313131.ref033","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05362-8","article-title":"How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014","volume":"20","author":"N. M. Hamzah","year":"2020","journal-title":"BMC Health Serv Res"},{"article-title":"National Health and Morbidity Survey 2019 Technical Report Volume II: Healthcare Demand","year":"2019","author":"M. of H. M. National Institute of Health (NIH)","key":"pone.0313131.ref034"},{"key":"pone.0313131.ref035","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.vhri.2020.07.168","article-title":"\u201cPDB9 Budget IMPACT Analysis of Empagliflozin in Type-2 Diabetes Patients with High Cardiovascular Risk in South Korea Based on Empa-REG OUTCOME\u00ae Trial: HIRA(HEALTH INSURANCE REVIEW & ASSESSMENT SERVICE)-NPS (NATIONAL PATIENTS SAMPLE) Database","volume":"22","author":"B. Kim","year":"2020","journal-title":"Value Health Reg Issues"},{"issue":"9","key":"pone.0313131.ref036","doi-asserted-by":"crossref","first-page":"A476","DOI":"10.1016\/j.jval.2017.08.440","article-title":"Budget Impact Analysis of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece","volume":"20","author":"G. Gourzoulidis","year":"2017","journal-title":"Value in Health"},{"issue":"12","key":"pone.0313131.ref037","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/dom.14535","article-title":"Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial","volume":"23","author":"M. Vaduganathan","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"pone.0313131.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110235","article-title":"Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations","volume":"9","author":"A. Lundqvist","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"pone.0313131.ref039","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/dme.14076","article-title":"Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial","volume":"36","author":"A. Kansal","year":"2019","journal-title":"Diabetic Medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:37:10Z","timestamp":1730396230000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313131"}},"subtitle":[],"editor":[{"given":"Amirmohammad","family":"Khalaji","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313131","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}